Table 2 TCGA database PRAD patient baseline data table.
From: SLC45A2 drives prostate cancer progression through tumor promotion and immune suppression
Characteristics | Low expression of SLC45A2 | High expression of SLC45A2 | P value |
|---|---|---|---|
n | 157 | 140 | |
Age, n (%) | 0.176 | ||
< = 60 | 64 (21.5%) | 68 (22.9%) | |
> 60 | 93 (31.3%) | 72 (24.2%) | |
Pathologic T stage, n (%) | 0.040 | ||
T2 | 98 (33%) | 4 (1.3%) | |
T3 | 55 (18.5%) | 85 (28.6%) | |
T4 | 4 (1.3%) | 51 (17.2%) | |
Pathologic N stage, n (%) | 0.048 | ||
N0 | 129 (43.4%) | 27 (9.1%) | |
N1 | 28 (9.4%) | 113 (38%) | |
Clinical T stage, n (%) | 0.024 | ||
T1 | 71 (23.9%) | 20 (6.7%) | |
T2 | 65 (21.9%) | 1 (0.3%) | |
T3 | 21 (7.1%) | 45 (15.2%) | |
T4 | 0 (0%) | 74 (24.9%) | |
Clinical M stage, n (%) | 0.029 | ||
M0 | 155 (52.2%) | 0 (0%) | |
M1 | 2 (0.7%) | 140 (47.1%) | |
Primary therapy outcome, n (%) | 0.018 | ||
PD | 14 (4.7%) | 113 (38%) | |
SD | 11 (3.7%) | 12 (4%) | |
PR | 17 (5.7%) | 5 (1.7%) | |
CR | 115 (38.7%) | 10 (3.4%) | |
OS event, n (%) | 0.006 | ||
Alive | 153 (51.5%) | 2 (0.7%) | |
Dead | 4 (1.3%) | 138 (46.5%) | |
DSS event, n (%) | 0.697 | ||
No | 154 (51.9%) | 139 (46.8%) | |
Yes | 3 (1%) | 1 (0.3%) | |
PFI event, n (%) | 0.423 | ||
No | 126 (42.4%) | 107 (36%) | |
Yes | 31 (10.4%) | 33 (11.1%) |
